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Abstract: Vitamin D deficiency and obesity are two public health problems extensively exacerbated
over the last years. Among the several mechanisms proposed to account for the complex
interplay between vitamin D and obesity, one that has gained particular attention is related to
the emerging role of obesity-related changes in gut microbiota and gut-derived metabolites, such
as Trimethylamine-N-oxide (TMAO). Vitamin D deficiency and high circulating TMAO levels
are associated with body weight and the severity of non-alcoholic fatty liver disease (NAFLD).
Considering the link of obesity with vitamin D on the one hand and obesity with TMAO on the other
hand, and the central role of the liver in both the vitamin D and TMAO metabolism, the aim of this
cross-sectional observational study was first, to confirm the possible inverse association between
vitamin D and TMAO across different body mass index (BMI) classes and second, to investigate if
this association could be influenced by the presence of NAFLD. One hundred and four adult subjects
(50 males and 54 females; 35.38 ± 7.49 years) were enrolled. The fatty liver index (FLI) was used
as a proxy for the diagnosis of NAFLD. Vitamin D deficiency was found in 65 participants (62.5%),
while 33 subjects (31.7%) had insufficient levels, and the remaining subjects had sufficient levels of
vitamin D. Subjects with both vitamin D deficiency and FLI-NAFLD had the highest TMAO levels
(p < 0.001). By stratifying the sample population according to the BMI classes, vitamin D levels
decreased significantly along with the increase of plasma TMAO concentrations, with the lowest
vitamin D levels and highest TMAO, respectively, in class III obesity. Vitamin D levels showed
significant opposite associations with circulating levels of TMAO (r = −0.588, p < 0.001), but this
association was no longer significant after the adjustment for FLI values. The highest values of TMAO
were significantly associated with the severity of obesity (OR 7.92; p < 0.001), deficiency of vitamin D
(OR 1.62; p < 0.001), and FLI-NAFLD (OR 3.79; p < 0.001). The most sensitive and specific cut-off for
vitamin D to predict the circulating levels of TMAO was ≤19.83 ng/mL (p < 0.001). In conclusion, our
study suggests that high TMAO levels are associated with vitamin D deficiency and NAFLD. Further
studies are required to investigate if there is a causality link or whether all of them are simply the
consequence of obesity.
Keywords: vitamin D; obesity; Trimethylamine N-oxide (TMAO); fatty liver index (FLI)
1. Introduction
Modern and westernised lifestyles, including smoking habits, physical inactivity, and an unhealthy
diet are considered one of the major culprits of the association between low vitamin D status and
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obesity [1]. Low sun exposure due to less outdoor activity and a sedentary lifestyle, vitamin D
sequestration, or volumetric dilution in fat mass are some of the factors playing a major role in the
pathogenesis of the hypovitaminosis D in patients with obesity [2,3]. Among the several mechanisms
proposed to account for the complex interplay between obesity and vitamin D [2,3], one that has gained
particular attention is related to the emerging role of obesity-related changes in gut microbiota and
gut-derived metabolites, such as Trimethylamine-N-oxide (TMAO) [4,5].
TMAO is a gut microbe-generated metabolite developed by a host’s flavin monooxygenase
3 (FMO3) in the liver, with an important role as a predictor of cardiovascular disease risk [6,7].
In particular, TMAO has been shown to exert a pro-atherogenic effect by affecting the metabolism of
cholesterol at different steps [5]. Skin 7-dehydrocholesterol is also a well-known precursor of vitamin
D [5]. A recent study reported a novel link between vitamin D and plasma TMAO concentrations
by showing that vitamin D supplementation at 12 months lowered plasma fasting TMAO levels [8].
Although the composite effect of age, sex, and creatinine was evaluated in this study, the possible
confounding effect of body weight and liver fat content was not considered. Of interest, there is
evidence that TMAO correlated positively with body mass index (BMI) [9], and that its levels increased
along with the classes of BMI [10]. In addition, TMAO has been reported to cause liver inflammation
and damage [11], and an adverse association between the circulating TMAO levels and the presence
and severity of non-alcoholic fatty liver disease (NAFLD) has also been reported [10,12].
Fatty liver index (FLI) is an accurate predictor of NAFLD which incorporates simple anthropometric
measurements; in particular, BMI and waist circumference (WC) and metabolic parameters, including
triglycerides and liver function [13], are considered a screening tool to identify NAFLD in subjects
with insulin resistance and cardio-metabolic risk factors where an ultrasound is unavailable [14,15]
and more recently also in lean-NAFLD subjects [16].
Currently, there are no studies available evidencing whether the adverse association between
vitamin D and TMAO could be differently affected by BMI and NAFLD. Considering the link of
obesity with vitamin D on the one hand and obesity with TMAO on the other hand, and the central
role of the liver in both the vitamin D and TMAO metabolism, the aim of this study was to evaluate
whether BMI and the presence of NAFLD assessed by FLI could influence the adverse link between
vitamin D and TMAO and to determine the cut off value of levels of vitamin D predictive of plasma
TMAO concentrations.
2. Materials and Methods
2.1. Design and Setting
This was a cross-sectional observational study carried out at the Department of Clinical Medicine
and Surgery, Unit of Endocrinology, University Federico II, Naples (Italy), from October 2016 to March
2019. The work was carried out in accordance with the Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans, and it was approved by the Ethical
Committee of the University of Naples “Federico II” Medical School (n. 173/16). The purpose of the
protocol was explained to all the study participants, and written informed consents were obtained.
2.2. Population Study
Recruitment strategies included a sample of 311 adult Caucasians subjects (21–56 years) of
both genders consecutively enrolled among patients of our outpatient clinic, hospital volunteers
and employees and residing in the Naples metropolitan area (latitude 40◦49′ N; elevation 17 m).
The subjects were evaluated from March through June 2018. All female subjects were non-pregnant
and non-lactating. A full medical history, including drug use, was collected.
In order to increase the homogeneity of the subject samples, we included only adults of both
genders with the following criteria of exclusion:
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• Impaired renal function (normal values: Estimated glomerular filtration rate ≥90 mL/min/1.73 m2
calculated by a chronic kidney disease epidemiology collaboration equation; Chronic Kidney
Disease Epidemiology Collaboration (CKD EPI) (9 subjects);
• Chronic liver diseases, viral hepatitis patients, hemochromatosis, hepatic malignancy (13 subjects);
• Presence of type 2 diabetes (T2DM) (defined by the criteria of the American Diabetes Association
as follows: Basal plasma glucose level ≥ 126 mg/dL on two occasions, or glycated haemoglobin
(HbA1c) ≥ 6.5% (≥48 mmoL/moL) on two occasions, or both at the same time. Participants on
antidiabetic medication were considered to have T2DM [17] (21 subjects);
• Uncontrolled thyroid or parathyroid disease (33 subjects);
• Clinical atherosclerosis (coronary artery disease, peripheral vascular disease) (36 subjects);
• Current therapy with calcium, vitamin D supplementation, or osteoporosis therapies,
anti-inflammatory drugs, statin and other hypolipidemic agents (41 subjects);
• User of antibiotics or probiotics within two months of recruitment (15 subjects);
• Specific nutritional regimens, including vegan or vegetarian diets (three subjects);
• Vitamin/mineral or antioxidant supplementation (29 subjects);
• Alcohol abuse according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-V
diagnostic criteria (7 subjects).
The flow chart of the studied subjects is shown in Figure 1.
Figure 1. The flow chart of the study subjects.
2.3. Anthropometric Measurements and Blood Pressure
Measurements were performed between 8 and 12 AM, after an overnight fast. The measurements
were made in a standard way by the same operator (a nutritionist experienced in providing nutritional
assessment and body composition). At the beginning of the study, all anthropometric measurements
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were taken with subjects wearing only light clothes and without shoes. For each subject, weight and
height were measured to calculate the BMI (weight (kg) divided by height squared (m2), kg/m2). Height
was measured to the nearest 0.5 cm using a wall-mounted stadiometer (Seca 711; Seca, Hamburg,
Germany). Body weight was determined to the nearest 0.1 kg using a calibrated balance beam scale
(Seca 711; Seca, Hamburg, Germany). BMI was classified according to (World Health Organization)
WHO’s criteria with a normal weight being 18.5–24.9 kg/m2; overweight, 25.0–29.9 kg/m2; grade I
obesity, 30.0–34.9 kg/m2; grade II obesity, 35.0–39.9 kg/m2; and grade III obesity ≥ 40.0 kg/m2 [18].
In accordance with the National Center for Health Statistics [19], WC was measured to the closest
0.1 cm using a non-stretchable measuring tape at the natural indentation or at a midway level between
the lower edge of the rib cage and iliac crest if no natural indentation was visible, as previously
reported [20–23].
2.4. Assay Methods
Samples were collected in the morning between 8 and 10 a.m., after an overnight fast of at least 8 h,
and stored at −80 ◦C until processed. All biochemical analyses including fasting plasma glucose, total
cholesterol, fasting plasma triglycerides, Alanine Transaminase (ALT), Aspartate Aminotransferase
(AST), and γ-Glutamyltransferase (γGT) were performed with a Roche Modular Analytics System in
the Central Biochemistry Laboratory of Federico II University Hospital (Naples, Italy). Low-density
lipoprotein (LDL) cholesterol and high-density lipoprotein HDL cholesterol were determined by a
direct method (homogeneous enzymatic assay for the direct quantitative determination of LDL and
HDL cholesterol). Fasting insulin levels were measured by a solid-phase chemiluminescent enzyme
immunoassay using commercially available kits (Immunolite Diagnostic Products Co, Los Angeles, CA,
USA), as previously reported in several studies [24–27]. Serum levels of vitamin D (25-OH vitamin D)
were measured with chemiluminescence (Liaison, DiaSorin, Saluggia, Italy). Vitamin D deficiency was
defined as a serum concentration of vitamin D < 20 ng/mL (50 nmoL/L), with insufficiency found in
levels between 21 and 29 ng/mL (from 52.5 to 72.5 nmoL/L), and normal levels being defined as values
of vitamin D ≥ 30 ng/mL (75 nmoL/L) [28]. TMAO serum levels were measured in samples stored at
−80 ◦C. A previous study indicated that, under these conditions, TMAO is stable for several years [29].
The quantification of plasma TMAO concentrations was performed using the method described by
Beale and Airs [30] and reported in our previous study [10,31]. Briefly, serum proteins were precipitated
with methanol (serum:methanol, 1:2, v/v); samples were vortex-mixed for 2 min, centrifuged at 14,000 g
for 10 min (4 ◦C) [32], and supernatants were collected and analyzed by the High Performance Liquid
Chromatography–Mass Spectrometry (HPLC/MS) method. Both HPLC/MS conditions and method
optimization were performed in accordance with Beale and Airs [30]. The HPLC system Jasco Extrema
LC-4000 system (Jasco Inc., Easton, MD, USA) was coupled to a single quadrupole mass spectrometer
(Advion ExpressIonL CMS, Advion Inc., Ithaca, NY, USA) equipped with an Electrospray ionization
(ESI) source, operating in positive ion mode. Chromatographic separation was performed with a
Luna HILIC column (150 × 3 mm, 5 µm particles) in combination with a guard column (HILIC),
both supplied by Phenomenex (Torrance, CA, USA). The intra-assay coefficients of variations (CV)
was <5.5%, as already widely reported in our previous studies [32–36]. FLI was calculated with the
formula: (FLI = eL/(1 + eL) × 100, L = 0.953 × loge triglycerides + 0.139 BMI + 0.718 × logeγGT + 0.053
×WC−15.745). The value of FLI that was considered as the cut-off value on the basis of Bedogni’s
criterion to detect the presence of NAFLD was 30 [13].
2.5. Statistical Analysis
Data distribution was evaluated by a Kolmogorov–Smirnov test and the abnormal data were
normalized by a logarithm. Skewed variables (BMI, TMAO, vitamin D, fasting glucose, insulin,
total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, ALT, AST, γGT, and FLI) were
back-transformed for presentation in tables and figures. Results are expressed as mean ± standard
deviation (SD). Differences according to the absence/presence of FLI-NAFLD were analyzed by a
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Student’s unpaired t-test. The differences among the vitamin D categories and classes of BMI were
analyzed by ANOVA followed by the Bonferroni post-hoc test. The correlations between study
variables were performed using Pearson r and correlation coefficients were estimated after adjusting for
FLI. Proportional Odds Ratio (OR) models, 95% Interval Confidence (IC), and R2, were performed to
assess the association among classes of BMI, vitamin D categories, and absence/presence of FLI-NAFLD.
Receiver operator characteristic (ROC) curve analysis was performed to determine sensitivity and
specificity, the area under the curve (AUC), and IC, as well as cut-off values of levels of vitamin D in
detecting circulating levels of TMAO. The test AUC for ROC analysis was also performed. To avoid
multicollinearity, variables with a variance inflation factor (VIF) > 10 were excluded. Values ≤0.05%
were considered statistically significant. Data were stored and analyzed using the MedCalc® package
(Version 12.3.0 1993–2012 MedCalc Software bvba—MedCalc Software, Mariakerke, Belgium).
3. Results
The study population consisted of 104 participants, 50 males and 54 females. The anthropometric
characteristics, systolic blood pressure (SBP) and diastolic blood pressure (DBP), plasma TMAO,
vitamin D, and metabolic profile of the study population are reported in Table 1. Most of the
participants had grade III obesity (27.9%) and vitamin D deficiency (62.5%). FLI-NAFLD was present
in more than half of the participants (59.6%).
Table 1. Anthropometric characteristics, blood pressure, plasma Trimethylamine-N-oxide (TMAO),
vitamin D, and metabolic profile of the study population.
Parameters Mean ± SD or Number (%)
Age (years) 35.38 ± 7.49
BMI (kg/m2) 33.52 ± 9.59
Normal weight 25, 24.0%
Overweight 23, 22.1%
Grade I obesity 15, 14.4%
Grade II obesity 12, 11.5%
Grade III obesity 29, 27.9%
WC (cm) 109.14 ± 24.34
SBP (mmHg) 124.27 ± 13.06
SDP (mmHg) 79.86 ± 10.46
Plasma TMAO (µM) 8.33 ± 3.28
Vitamin D (ng/mL) 17.69 ± 6.44
Deficiency 65, 62.5%
Insufficiency 33, 31.7%
Normal 6, 5.8%
Fasting Glucose (mg/dL) 100.56 ± 17.48
Insulin (µU/mL) 13.68 ± 12.57
Total cholesterol (mg/dL) 184.65 ± 40.00
HDL cholesterol (mg/dL) 46.50 ± 12.10
LDL cholesterol (mg/dL) 111.51 ± 42.69
Triglycerides (mg/dL) 139.30 ± 54.74
ALT (U/L) 31.96 ± 15.25
AST (U/L) 32.49 ± 15.61
γGT (U/L) 35.71 ± 20.04
FLI 63.78 ± 33.89
FLI NAFLD (presence) 62, 59.6%
A p value in bold denotes a significant difference (p < 0.05).
Plasma TMAO concentrations across vitamin D categories and according to presence/absence of
FLI-NAFLD are reported in Figures 2 and 3, respectively. The highest plasma TMAO concentrations
were present in the subjects with a vitamin D deficiency and FLI-NAFLD, p < 0.001 (Figures 2 and 3,
respectively).
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Figure 2. The circulating levels of TMAO in the population study across vitamin D categories. A p value
in bold denotes a significant difference (p < 0.05); n = number.
Figure 3. Circulating levels of TMAO in the population study classified according to presence/absence
of FLI-NAFLD. A p value in bold denotes a significant difference (p < 0.05); n = number.
Table 2 shows the anthropometric characteristics and metabolic profile of the population grouped
on the base of BMI categories. As reported in Table 2, no differences were observed in age (p = 0.063),
while compared with normal-weight subjects, subjects who were overweight and those with obesity
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exhibited statistical differences in all study parameters (p < 0.001). Stratifying the sample population
according to the BMI classes, vitamin D decreased significantly along with the increase of circulating
levels of TMAO, with the lowest vitamin D levels and highest TMAO, respectively, in class III obesity.
Table 2. Age, anthropometric measurements, and metabolic profile of participants grouped on the
basis of BMI categories.
Parameters Normal Weightn = 25; 24.0%
Over Weight
n = 23; 22.1%
Grade I Obesity
n = 15; 14.4%
Grade II
Obesity
n = 12; 11.5%
Grade III
Obesity
n = 29; 27.9%
p-Value
Age (years) 32.64 ± 7.55 38.35 ± 7.40 37.60 ± 6.45 35.00 ± 8.68 34.41 ± 6.81 0.063
BMI (kg/m2) 23.11 ± 1.59 27.34 ± 1.24 32.37 ± 1.47 37.58 ± 1.43 46.31 ± 5.31 <0.001
WC (cm) 84.17 ± 10.66 95.60 ± 12.21 109.41 ± 8.08 117.91 ± 14.33 137.64 ± 16.41 <0.001
Plasma TMAO (µM) 3.53 ± 2.49 8.32 ± 0.70 9.17 ± 1.11 9.94 ± 0.90 11.39 ± 1.03 <0.001
Vitamin D (ng/mL) 23.69 ± 6.35 20.29 ± 3.94 17.27 ± 4.52 14.78 ± 2.45 11.89 ± 4.11 <0.001
Fasting Glucose (mg/dL) 85.60 ± 10.57 95.78 ± 13.15 98.33 ± 13.76 97.00 ± 12.28 119.89 ± 11.15 <0.001
Insulin (µU/mL) 2.66 ± 1.15 7.16 ± 5.66 10.64 ± 5.65 14.51 ± 10.77 29.57 ± 9.14 <0.001
Total cholesterol (mg/dL) 151.36 ± 20.99 175.61 ± 27.92 168.67 ± 24.38 211.58 ± 43.25 217.66 ± 35.08 <0.001
HDL cholesterol (mg/dL) 57.32 ± 8.45 51.43 ± 6.74 41.93 ± 13.38 41.67 ± 10.59 37.62 ± 8.98 <0.001
LDL cholesterol (mg/dL) 74.77 ± 23.59 99.33 ± 25.22 99.51 ± 16.81 138.05 ± 46.00 147.67 ± 40.54 <0.001
Triglycerides (mg/dL) 96.36 ± 26.22 124.22 ± 21.03 174.47 ± 64.77 159.33 ± 35.22 161.83 ± 65.63 <0.001
ALT (U/L) 23.84 ± 6.53 25.08 ± 9.96 36.47 ± 11.30 37.58 ± 17.71 39.76 ± 19.22 <0.001
AST (U/L) 21.56 ± 5.95 27.73 ± 6.53 35.70 ± 15.27 39.08 ± 15.44 41.28 ± 19.81 <0.001
γGT (U/L) 25.20 ± 7.51 25.65 ± 10.81 38.13 ± 15.93 40.00 ± 14.70 49.72 ± 27.02 <0.001
FLI 19.83 ± 13.66 45.02 ± 20.58 78.67 ± 11.27 89.88 ± 7.33 98.04 ± 2.55 <0.001
FLI-NAFLD (presence) 0, 0% 7, 30.4% 14, 93.3% 12, 100% 29, 100% <0.001
A p value in bold denotes a significant difference (p < 0.05).
Correlation Analysis
The correlations of vitamin D and TMAO levels with age, anthropometric measurements, and
metabolic profile are summarized in Table 3. Apart from age, vitamin D and circulating levels of
TMAO showed significant opposite associations with all parameters. Figure 4 shows the correlation
between vitamin D levels and plasma TMAO concentrations (r = −0.588, p < 0.001). The association
was no longer evident after adjusting for FLI-NAFLD (r = −0.123, p= 0.215).
Table 3. Correlations of vitamin D levels and plasma TMAO with age, anthropometric measurements,
and metabolic profile.
Parameters Vitamin D (ng/mL) TMAO (µM)
r p-Value r p-Value
Age (years) −0.055 0.580 0.174 0.078
BMI (kg/m2) −0.752 <0.001 0.827 <0.001
WC (cm) −0.631 <0.001 0.741 <0.001
Fasting Glucose (mg/dL) −0.561 <0.001 0.756 <0.001
Insulin (µU/mL) −0.654 <0.001 0.656 <0.001
Total cholesterol (mg/dL) −0.493 <0.001 0.631 <0.001
HDL cholesterol (mg/dL) 0.482 <0.001 −0.676 <0.001
LDL cholesterol (mg/dL) −0.502 <0.001 0.653 <0.001
Triglycerides (mg/dL) −0.491 <0.001 0.495 <0.001
ALT (U/L) −0.351 <0.001 0.417 <0.001
AST (U/L) −0.301 <0.001 0.502 <0.001
γGT (U/L) −0.339 <0.001 0.462 <0.001
FLI −0.647 <0.001 0.826 <0.001
A p value in bold denotes a significant difference (p < 0.05).
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Figure 4. Correlations between plasma vitamin D levels and plasma TMAO concentrations. A p value
in bold denotes a significant difference (p < 0.05).
The results of the bivariate proportional OR model performed to assess the association of TMAO
with quantitative variables are reported in Table 4. The highest values of TMAO were significantly
associated with the severity of obesity (OR 7.92; p < 0.001), deficiency of vitamin D (OR 1.62; p < 0.001),
and FLI-NAFLD (OR 3.79; p < 0.001).
Table 4. Bivariate proportional odds ratio model to assess the association between circulating levels of
TMAO and vitamin D categories and FLI-NAFLD.
Parameters Circulating Levels of TMAO (µM)
OR p-Value 95% IC R2
BMI
Normal weight 0.08 0.004 0.016–0.465 0.588
Overweight 0.99 0.009 0.866–1.150 0.232
Grade I obesity 0.06 0.004 0.915–1.345 0.012
Grade II obesity 0.02 0.002 0.972–1.650 0.038
Grade III obesity 7.92 <0.001 3.174–19.77 0.525
Vitamin D
Deficit 1.62 <0.001 1.32–1.99 0.302
Insufficiency 0.75 <0.001 0.65–0.87 0.161
Sufficiency 0.68 0.004 0.53–0.89 0.094
FLI-NAFLD 3.79 <0.001 2.06–6.89 0.518
A p value in bold denotes a significant difference (p < 0.05).
A ROC analysis was then performed to determine the cut off value of levels of vitamin D predictive
of plasma TMAO concentrations. In particular, levels of vitamin D ≤ 19.83 ng/mL (p < 0.001, AUC 0.846,
standard error 0.037, 95% CI 0.762 to 0.909; Figure 5) could serve as a threshold for significantly
increased plasma TMAO concentrations above the median (8.95 µM).
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Figure 5. The receiver operator characteristic (ROC) for predictive values of levels of vitamin D in
detecting plasma TMAO concentrations. A p value in bold denotes a significant difference (p < 0.05).
4. Discussion
In this cross-sectional, observational study, we reported an inverse association between vitamin
D and plasma TMAO concentrations in a sample of an adult population stratified according to the
categories of BMI and FLI-NAFLD. To the best of our knowledge, this has been the first study to report
a negative association between vitamin D and plasma TMAO concentrations in subjects with obesity.
When considering the entire sample population, higher plasma levels of TMAO were observed
in study participants with a vitamin D deficiency and in those with presence of FLI-NAFLD.
The stratification of the study population according to the BMI classes allowed us to confirm the
negative relationship between vitamin D and plasma TMAO concentrations. However, we extended
the knowledge on the relationship between vitamin D and TMAO as we observed that this negative
association increased along with the BMI; the highest plasma TMAO concentrations were associated
with the lowest levels of vitamin D in study participants with class III BMI. In addition, higher plasma
TMAO concentrations were significantly associated not only with the severity of obesity and vitamin
D deficiency, but also with the presence of FLI-NAFLD. Of interest, the negative association between
vitamin D and TMAO was no longer evident after adjusting for FLI-NAFLD. Finally, using ROC curve
analysis, vitamin D levels ≤ 19.83 ng/mL predicted the highest plasma TMAO concentrations.
The negative association between vitamin D and TMAO was actively linked to obesity and
obesity-related disorders in an opposite way, which suggests that some considerations need to be
taken into account. Epidemiologic studies have reported an association between vitamin D deficiency
with cardiovascular risk factors and adverse cardiovascular outcomes [33]. In a meta-analysis of
prospective cohort studies based on a large sample population [34], adjusted risk of cardiovascular
mortality was 57% higher in the lowest category than in the highest category of vitamin D levels [35].
However, albeit vitamin D has been suggested as a protective cardiovascular disease risk factor [36,37],
the scientific evidence still remains inconclusive [38]. In this complex interplay, it could be hypothesized
that vitamin D deficiency could have a direct role in determining the increased risk of developing
cardiovascular diseases but also that vitamin D deficiency and cardiovascular risk could be both
determined by obesity [39,40]. However, it cannot be overlooked that vitamin D deficiency may
contribute to worsening cardiovascular health in obesity through several direct mechanisms, including
activation of the renin-angiotensin-aldosterone system, which can predispose obese individuals to
hypertension and left ventricular hypertrophy or an increase in the parathyroid hormone, which
increases insulin resistance, downregulation proinflammatory cytokines and metalloproteinases,
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upregulation of anti-inflammatory cytokines, and inhibitors of metalloproteinases [41,42]. The opposite
association of vitamin D levels and plasma TMAO concentrations across BMI classes and the presence
of FLI-NAFLD allowed us to speculate that the increased plasma TMAO concentrations could be a
further mechanism through which vitamin D deficiency could contribute to worsening cardiovascular
risk in subjects with obesity.
Plasma TMAO concentrations increase after the gut microbial metabolism of high-fat food found
in the Western Diet, including red meat, eggs, and dairy products, which are rich in L-carnitine and
choline. The metabolic pathway of TMAO includes the digestion of these amines from gut microbiota
with the production of trimethylamine, which is then converted to TMAO via FMO3 in the liver [43,44].
Randrianarisoa et al. [9] reported that TMAO correlated positively with BMI, insulin resistance, visceral
fat mass, and liver fat content [9]. Very recently, we reported a novel association between circulating
levels of TMAO and the Mediterranean diet in healthy normal-weight adults, with a clear gender
difference in this association [31], and FLI [10].
A large body of evidence supports the association of TMAO with increased cardiovascular risk.
A recent meta-analysis of 11 prospective cohort studies indicated that plasma TMAO correlated with a
23% increase in risk for cardiovascular events ((hazard ratio) HR 1.23, 95% CI 1.07 to 1.42) and a 55%
increase in all-cause mortality [45]. Given the association between TMAO and cardiovascular risk and
the tight link between gut microbiota and obesity/obesity-related diseases, it has been hypothesized
that the TMAO pathway may also be mechanistically linked to the pathogenesis of obesity [46].
Obeid R et al. reported that a 12-month supplementation of vitamin D was effective in lowering
plasma fasting TMAO and increasing plasma choline, a TMAO precursor and basic component for the
synthesis of phosphatidylcholine, which in turn is necessary for promoting lipid exportation from
the liver [8]. The authors suggested that their findings were the result of the vitamin D effect on the
metabolism of choline, a dietary nutrient whose deficiency is linked to the accumulation of hepatic
lipid [47]. As a further linking mechanism, obesity-related vitamin D deficiency could blunt gut
homeostasis, i.e., the regulation of the integrity of the intestinal epithelium and the mucosal immune
system along with the microbial communities, thus altering TMAO pathway [48,49].
On the other hand, TMAO and TMAO-producing enzyme FMO3 in the liver affect the metabolism
of cholesterol by altering the enterohepatic cholesterol and bile acid metabolism [5]. Thus, it is
conceivable that TMAO could also affect the metabolism of 7-dehydrocholesterol, the skin precursor
of vitamin D, lending support to the hypothesis that the interactions between vitamin D and TMAO
could be bidirectional.
The results of this study confirmed, however, that the presence of FLI-NAFLD was significantly
and positively associated with plasma TMAO concentrations, while also highlighting that the inverse
association between vitamin D levels and plasma TMAO concentrations was no longer significant
after adjusting for FLI-NAFLD presence. The liver has an important role in the metabolism of
both vitamin D and TMAO through 25-hydroxyvitamin D-hydroxylase and the TMAO-producing
enzyme FMO3, respectively. On the other hand, vitamin D deficiency is involved in an increased
hepatic lipogenesis and a reduced beta-oxidation, which leads to the accumulation of fat in the liver,
accompanied by insulin resistance [50]; however, no direct associations between vitamin D deficiency
and severity of liver steatosis has been reported in humans [51]. In addition, very recently, it was
demonstrated that, in animal models, TMAO impaired liver function and increased hepatic triglyceride
accumulation and lipogenesis, while in humans, TMAO worsened liver steatosis by modulating bile
acid metabolism, by shifting their hepatic composition toward a farnesoid X receptor-antagonistic
activity [52]. Thus, a bidirectional relationship could operate also between TMAO and NAFLD. FLI is a
surrogate marker of a fatty liver widely used as a screening tool to identify NAFLD in epidemiological
studies [14–16]. Of interest, Miao et al. [10,53] found that an animal model characterized by a selective
hepatic insulin resistance has increased circulating TMAO levels associated with the up-regulation of
the TMAO-producing enzyme FMO3 in the liver. In this context, hepatic FMO3 is a target of insulin
action [53] and its activity is boosted in the condition of insulin resistance [54]. Therefore, the link
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between TMAO and cardiovascular diseases might represent the epiphenomenon of hepatic insulin
resistance. However, it has been proposed that TMAO alone could affect hepatic triglycerides levels
and alter the synthesis and transport of bile acids [12], while the addition of 0.2% TMAO for four
weeks in mice on a high-fat diet impaired glucose tolerance, blocked the hepatic insulin signaling
pathway, and caused adipose tissue inflammation [55], thus paving the way to the development of
NAFLD, the metabolic disease of the liver associated with insulin resistance. Accordingly, studies in
humans have confirmed the positive association of circulating TMAO levels with the presence and
severity of NAFLD, both by ultrasonographic NAFLD evaluation [12] and FLI, and also independently
of common confounding variables, including BMI [10].
The cross-sectional design is the main limitation of this study, as it does not allow the identification
of any causal association between low vitamin D status and increased plasma TMAO concentrations.
In addition, we did not include an analysis of gut microbiota, nutritional assessment, or evaluation
of metabolic precursor of TMAO, such as choline, betaine, or carnitine. However, the study of gut
microbiota is burdened by a high intra-individual variability that might affect the interpretation of the
results [56–59]. In addition, the influence of diet on fasting TMAO concentrations, albeit statistically
significant, could be considered rather moderate [31,60]. Moreover, although the liver biopsy is the
gold-standard technique for identifying NAFLD, we used a surrogate marker of NAFLD which is FLI
that has been demonstrated to be tightly correlated to the assessment of NAFLD by an ultrasound.
Moreover, a liver biopsy is an invasive procedure burdened with rare but potentially life-threatening
complications, whereas FLI has proved to represent an easy screening tool to identify NAFLD in
patients with cardio-metabolic risk factors [13,61,62]. Due to the lack of a liver biopsy, the association
between vitamin D and TMAO in the setting of NAFLD should be investigated in a future study.
Finally, our study was based on a single clinical center, with a possibility of selection bias in the results.
Nonetheless, the single-center study allowed us to increase the homogeneity of the sample as we
included participants living in the same geographical area, with the same effect of latitude on vitamin
D levels and, likely, with a similar nutrient availability and food consumption pattern. Nevertheless,
a major strength of this study is the stratification of our sample population across BMI classes, and the
inverse association between vitamin D status and plasma TMAO levels in each group was compared
and evaluated with that of the other groups. In addition, we carefully excluded from the enrollment
those participants who had any of the main known factors that can affect TMAO metabolism, such as
impaired renal or liver function, T2DM, and alcohol abuse.
In conclusion, our study further extends the knowledge on the adverse link between vitamin D
and TMAO as a possible adjunctive factor involved in cardiovascular risk in obesity. The results of our
study allowed us to speculate that the role of TMAO as a marker of cardiovascular risk could also be
mediated through its association with a low vitamin D status or the presence of NAFLD in subjects
with obesity. However, the potential translational application of the results of this study into clinical
practice requires large-scale data to confirm the inverse association between vitamin D and plasma
TMAO concentrations in obesity and obesity-related diseases and to clarify the causality, if any.
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